HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PTC-028

Note: structural analog of PTC596

Also Known As:

6-(5,6-Difluoro-2-methyl-1H-benzimidazol-1-yl)-N-(4-(trifluoromethyl)phenyl)-2-pyrazinamine

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - PTC-028: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - PTC-028: 4

Experts

1.	Weetall, Marla: 3 articles (12/2020 - 10/2018)
2.	Bhattacharya, Resham: 2 articles (10/2018 - 01/2018)
3.	Cao, Liangxian: 2 articles (10/2018 - 01/2018)
4.	Crim, Aleia: 2 articles (10/2018 - 01/2018)
5.	Dey, Anindya: 2 articles (10/2018 - 01/2018)
6.	Dwivedi, Shailendra Kumar Dhar: 2 articles (10/2018 - 01/2018)
7.	Mukherjee, Priyabrata: 2 articles (10/2018 - 01/2018)
8.	Furukawa, Yoichi: 1 article (12/2020)
9.	Ito, Ryoji: 1 article (12/2020)
10.	Iwama, Atsushi: 1 article (12/2020)

Related Diseases

1.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/01/2020 - "Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome." 12/01/2020 - "We herein investigated the efficacy of PTC-028, a structural analog of PTC596, for myelodysplastic syndrome (MDS). "
2.	Neoplasms (Cancer) 01/01/2018 - "We report that PTC-028 treatment selectively inhibits cancer cells in clonal growth and viability assays, whereas normal cells remain unaffected. " 10/01/2018 - "In an aggressive uterine carcinosarcoma xenograft model, single-agent PTC-028 significantly delayed tumor growth and increased tumor doubling time compared with the standard carboplatin/paclitaxel therapy. "
3.	Endometrial Neoplasms (Endometrial Cancer) 10/01/2018 - "PTC-028, a second-generation inhibitor of BMI1 function, decreases invasion of endometrial cancer cells and potentiates caspase-dependent apoptosis, while normal cells with minimal expression of BMI1 remain unaffected. "
4.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2018 - "Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer." 01/01/2018 - "In vivo, orally administered PTC-028, as a single agent, exhibits significant antitumor activity comparable with the standard cisplatin/paclitaxel therapy in an orthotopic mouse model of ovarian cancer. "
5.	Multiple Myeloma 01/01/2020 - "The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene."

Related Drugs and Biologics

1.	PTC596
2.	Tubulin Modulators
3.	Paclitaxel (Taxol)
4.	Carboplatin (JM8)
5.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Therapeutics